0808 GMT - Novo Nordisk's downgraded guidance assumes a meaningful uplift of Wegovy volumes in the second half of the year and analysts at Morgan Stanley think the top end of the new guidance is still demanding. The guidance cut implies a 1% cut to consensus sales and EBIT at constant exchange rates but a 4% cut on sales and 6% cut on EBIT including currencies, the bank says. First quarter Wegovy sales missed expectations by 7%, impacted by destocking in the U.S. and compounding competition. Novo Novo also noted lower realized prices. Ozempic beat by 3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
May 07, 2025 04:08 ET (08:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。